Navigating the UK medical device market can be a complex journey. For biotech and SME companies, understanding the regulatory landscape is crucial to efficiently and safely bringing innovative products to patients. As someone deeply involved in this field, I know that medical device entry consulting is not just about ticking boxes; it’s about creating a strategic pathway that accelerates market access while ensuring compliance and patient safety.

The EU AI Act (Artificial Intelligence Act Regulation EU 2024/1689), which came into force on 1 August 2024, establishes a harmonised framework for regulating AI systems. It impacts the use of AI in medical settings, particularly when integrated with the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

In this article, we will explore how AI is reshaping the pharmaceutical landscape and examine its implications for the workforce, presenting a balanced view on the potential benefits and challenges ahead.

In 2025, manufacturers of AI-powered medical devices face a new regulatory reality. The European Union has introduced the Artificial Intelligence Act (AIA). If your device falls under the Medical Device Regulation (MDR) or the In Vitro Diagnostic Regulation (IVDR), the AIA is mandatory. It’s now a core part of your compliance strategy.

In the fast-paced world of drug discovery, artificial intelligence (AI) has become essential, transforming the way researchers identify...

The digital health landscape is evolving quickly, thanks to advances in technology like artificial intelligence (AI) and machine learning...